240 related articles for article (PubMed ID: 18721711)
1. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.
Bucci FA; Waterbury LD
J Cataract Refract Surg; 2008 Sep; 34(9):1509-12. PubMed ID: 18721711
[TBL] [Abstract][Full Text] [Related]
2. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
Bucci FA; Waterbury LD
Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
[TBL] [Abstract][Full Text] [Related]
3. Concentration and dosing of ketorolac versus bromfenac.
Gayton J
J Cataract Refract Surg; 2009 Jul; 35(7):1319; author reply 1320. PubMed ID: 19545832
[No Abstract] [Full Text] [Related]
4. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification.
Bucci FA; Waterbury LD
Curr Med Res Opin; 2011 Dec; 27(12):2235-9. PubMed ID: 21992076
[TBL] [Abstract][Full Text] [Related]
5. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.
Heier JS; Awh CC; Busbee BG; Waterbury LD; Daniel P; Stoller GL; Cleary TS
Retina; 2009 Oct; 29(9):1310-3. PubMed ID: 19934822
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
Walters T; Raizman M; Ernest P; Gayton J; Lehmann R
J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
Bucci FA; Waterbury LD
Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification.
Bucci FA; Waterbury LD; Amico LM
Am J Ophthalmol; 2007 Jul; 144(1):146-7. PubMed ID: 17601444
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.
Waterbury LD; Silliman D; Jolas T
Curr Med Res Opin; 2006 Jun; 22(6):1133-40. PubMed ID: 16846546
[TBL] [Abstract][Full Text] [Related]
10. Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor.
Miyake K; Ogawa T; Tajika T; Gow JA; McNamara TR
J Ocul Pharmacol Ther; 2008 Dec; 24(6):573-8. PubMed ID: 19049295
[TBL] [Abstract][Full Text] [Related]
11. Bromfenac ophthalmic solution 0.09 %: human aqueous humor concentration detected by high-performance liquid chromatography.
Macrì A; Vagge A; Salis A; Fucile C; Marini V; Martelli A; Giuffrida S; Iester M; Damonte G; Mattioli F
Int Ophthalmol; 2017 Apr; 37(2):417-421. PubMed ID: 27324371
[TBL] [Abstract][Full Text] [Related]
12. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery.
Miyanaga M; Miyai T; Nejima R; Maruyama Y; Miyata K; Kato S
Acta Ophthalmol; 2009 May; 87(3):300-5. PubMed ID: 19183412
[TBL] [Abstract][Full Text] [Related]
13. Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.
Waterbury LD; Galindo D; Villanueva L; Nguyen C; Patel M; Borbridge L; Attar M; Schiffman RM; Hollander DA
J Ocul Pharmacol Ther; 2011 Apr; 27(2):173-8. PubMed ID: 21351868
[TBL] [Abstract][Full Text] [Related]
14. Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
Bucci FA; Waterbury LD
J Cataract Refract Surg; 2008 Aug; 34(8):1226; author reply 1226-7. PubMed ID: 18655957
[No Abstract] [Full Text] [Related]
15. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
Donnenfeld ED; Holland EJ; Stewart RH; Gow JA; Grillone LR;
Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
[TBL] [Abstract][Full Text] [Related]
16. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
Silverstein SM; Cable MG; Sadri E; Peace JH; Fong R; Chandler SP; Gow JA; Klier SM; McNamara TR;
Curr Med Res Opin; 2011 Sep; 27(9):1693-703. PubMed ID: 21751945
[TBL] [Abstract][Full Text] [Related]
17. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent.
Jones J; Francis P
Expert Opin Pharmacother; 2009 Oct; 10(14):2379-85. PubMed ID: 19735215
[TBL] [Abstract][Full Text] [Related]
18. REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1.
Russo A; Morescalchi F; Vezzoli S; Bernini M; Turano R; Costagliola C; De Ferrari F; Semeraro F
Retina; 2016 Jun; 36(6):1227-31. PubMed ID: 26562569
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom.
Si EC; Bowman LM; Hosseini K
J Ocul Pharmacol Ther; 2011 Feb; 27(1):61-6. PubMed ID: 21332395
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.
Henderson BA; Gayton JL; Chandler SP; Gow JA; Klier SM; McNamara TR;
Ophthalmology; 2011 Nov; 118(11):2120-7. PubMed ID: 21762992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
